Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Rechanneling a CTO in a Non-Infarct-Related Artery After Primary PCI: Yes or No?

cto rechannelling primary PCIBetween 10% and 15% of patients admitted with ST-segment elevation myocardial infarction present concurrent coronary chronic total occlusion (CTO) in a non-infarct-related artery, which is associated with increased morbidity and mortality.

 

The EXPLORE (Evaluating Xience and Left Ventricular Function in Percutaneous Coronary Intervention on Occlusions After ST-Elevation Myocardial Infarction) trial evaluated whether patients admitted with acute myocardial infarction and concurrent chronic total occlusion benefit from rechanneling such a vessel shortly after primary angioplasty.

 

From November 2007 to April 2015, the trial enrolled 304 patients with acute ST-segment elevation myocardial infarction who underwent primary angioplasty in the infarct-related artery in 14 centers in Europe and Canada and had concurrent chronic total occlusion.

 

A total of 150 patients were randomly assigned to undergo an attempt at rechanneling the occlusion shortly after primary angioplasty, and the remaining 154 patients were assigned to conservative treatment without attempting rechanneling.

 

The primary endpoints were left ventricular function and end diastolic volume on magnetic resonance imaging at four months.

 

Success rate for the rechanneling attempt was 77%.

 

At four months, the left ventricular function was similar for both groups:

 

Rechanneling treatment group: 44.1 ± 12.2%

Conservative treatment group: 44.8 ± 11.9%

(p = 0.60)

 

Something similar happened with the end diastolic volume:

Rechanneling treatment group: 215.6 ± 62.5 ml

Conservative treatment group: 212.8 ± 60.3 ml

(p = 0.70)

 

Subgroup analysis showed that patients with total occlusions located in the anterior descending artery benefited from improved ventricular function after rechanneling, when compared with patients who received conservative treatment.

 

Patients with total occlusions in the anterior descending artery: 47.2 ± 12.3%

Patients who received conservative treatment: 40.4 ± 11.9%

(p = 0.02)

 

There were no differences as regards adverse coronary events at four months (5.4% vs. 2.6%; p = 0.25).

 

Conclusion

Rechanneling of a chronic total occlusion in a non-infarct-related vessel within a week after primary angioplasty was feasible and safe. However, it offered no benefit in terms of improved ventricular function or end diastolic volume when compared to primary angioplasty associated with conservative treatment for total occlusion.

 

The subgroup analysis must be confirmed through further investigation.

 

Original title: Percutaneous Intervention for Concurrent Chronic Total Occlusions in Patients with STEMI. The EXPLORE Trial.

Reference: José P.S. Henriques et al. J Am Coll Cardiol. 2016;68(15):1622-1632.


 

Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

 

We value your opinion. You are more than welcome to leave your comments, suggestions or questions here below.

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...